Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots.

Journal: Journal of visualized experiments : JoVE
PMID:

Abstract

The emergence of the recent SARS-CoV-2 global health crisis introduced key challenges for epidemiological research and clinical testing. Characterized by a high rate of transmission and low mortality, the COVID-19 pandemic necessitated accurate and efficient diagnostic testing, particularly in closed populations such as residential universities. Initial availability of nucleic acid testing, like nasopharyngeal swabs, was limited due to supply chain pressure which also delayed reporting of test results. Saliva-based reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) testing has shown to be comparable in sensitivity and specificity to other testing methods, and saliva collection is less physically invasive to participants. Consequently, we developed a multiplex RT-qPCR diagnostic assay for population surveillance of Clemson University and the surrounding community. The assay utilized open-source liquid handling robots and thermocyclers instead of complex clinical automation systems to optimize workflow and system flexibility. Automation of saliva-based RT-qPCR enables rapid and accurate detection of a wide range of viral RNA concentrations for both large- and small-scale testing demands. The average turnaround for the automated system was < 9 h for 95% of samples and < 24 h for 99% of samples. The cost for a single test was $2.80 when all reagents were purchased in bulk quantities.

Authors

  • Rachel E Ham
    Center for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University.
  • Austin R Smothers
    Center for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University; Department of Bioengineering, Clemson University.
  • Kylie L King
    Center for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University.
  • Justin M Napolitano
    Center for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University.
  • Theodore J Swann
    Swann Medicine.
  • Lesslie G Pekarek
    Student Health Services, Clemson University.
  • Mark A Blenner
    Center for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University; Department of Chemical & Biomolecular Engineering, Clemson University; Department of Chemical & Biomolecular Engineering, University of Delaware.
  • Delphine Dean
    Center for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University; Department of Bioengineering, Clemson University; finou@clemson.edu.